GlassScriptPhysician profile
Van Q Nguyen
NPI 1205898236
$17,326.62
in general payments reported to CMS, 2019-2025
25 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $5,706 · 2021: $162 · 2022: $100 · 2023: $194 · 2024: $436 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,783.35 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $453.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $333.62 | 2019-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $235.06 | 2024-2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $222.87 | 2019-2025 | |
| Amarin Pharma, INC. | $217.18 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.66 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $205.56 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.17 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $72.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $65.51 | 2019-2020 | |
| Esperion Therapeutics, INC. | $62.38 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $45.00 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $42.95 | 2024 | Opsumit, Uptravi |
| Nuwellis, INC. | $35.88 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $31.74 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $29.25 | 2024 | |
| Kestra Medical Technology Services, INC. | $25.69 | 2023 | Assure Wcd |
| Chiesi USA, INC. | $25.27 | 2019 | |
| Boston Scientific Corporation | $18.90 | 2019 | |
| Biosense Webster, INC. | $17.80 | 2025 | Carto 3 |
| Bayer Healthcare Pharmaceuticals INC. | $17.31 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.